Cancer patients frequently use complementary medicine. Curcumin (CUR) and its derivates (from the extract of Curcuma longa L.) represent some of the most frequently used ones, having a long history in traditional Asian medicine. CUR was demonstrated, both in vitro and in vivo, to have significant anti-inflammatory effects, thus potentially counteracting cancer-promoting inflammation, which is a hallmark of cancer. CUR modulate a plethora of signaling pathways in cancer cells, comprising the NF-κB (nuclear factor k-light-chain-enhancer of activated B cells), the JAK/STAT (Janus-Kinase/Signal Transducers and Activators of Transcription), and the TGF-β (transforming growth factor-β) pathways. Furthermore, CUR confers properties of electron receptors, which destabilize radical oxygen species (ROS), explaining its antioxidant and anti-apopototic effects. Although CUR has a low bioavailability, its role in advanced cancer treatment and supportive care was addressed in numerous clinical trials. After promising results in phase I–II trials, multiple phase III trials in different indications are currently under way to test for direct anti-cancer effects. In addition, CUR exerts beneficial effects on cancer treatment-related neurotoxcity, cardiotoxicity, nephrotoxicity, hemato-toxicity, and others. More efficient galenic formulations are tested to optimze CUR’s usability in cancer treatment. This review should provide a comprehensive overview of basic science, and pre-clinical and clinical data on CUR in the field of oncology.
(1) Background: Liquid biopsy (LB) is a novel diagnostic method with the potential of revolutionizing the prevention, diagnosis, and treatment of several solid tumors. The present paper aims to summarize the current knowledge and explore future possibilities of LB in the management of metastatic gastric cancer. (2) Methods: This narrative review examined the most recent literature on the use of LB-based techniques in metastatic gastric cancer and the current LB-related clinical trial landscape. (3) Results: In gastric cancer, the detection of circulating cancer cells (CTCs) has been recognized to have a prognostic role in all the disease stages. In the setting of localized disease, cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) qualitative and quantitative detection have the potential to inform on the risk of cancer recurrence and metastatic dissemination. In addition, gastric cancer-released exosomes may play an essential part in metastasis formation. In the metastatic setting, the levels of cfDNA show a positive correlation with tumor burden. There is evidence that circulating tumor microemboli (CTM) in the blood of metastatic patients is an independent prognostic factor for shorter overall survival. Gastric cancer-derived exosomal microRNAs or clonal mutations and copy number variations detectable in ctDNA may contribute resistance to chemotherapy or targeted therapies, respectively. There is conflicting and limited data on CTC-based PD-L1 verification and cfDNA-based Epstein–Barr virus detection to predict or monitor immunotherapy responses. (4) Conclusions: Although preliminary studies analyzing LBs in patients with advanced gastric cancer appear promising, more research is required to obtain better insights into the molecular mechanisms underlying resistance to systemic therapies. Moreover, validation and standardization of LB methods are crucial before introducing them in clinical practice. The feasibility of repeatable, minimally invasive sampling opens up the possibility of selecting or dynamically changing therapies based on prognostic risk or predictive biomarkers, such as resistance markers. Research is warranted to exploit a possible transforming area of cancer care.
Gastrointestinal (GI) tumors account for a quarter of all the cancer burden and a third of the global cancer-related mortality. Among them, some cancers retain a dismal prognosis; therefore, newer and innovative therapies are urgently needed in priority disease areas of high-unmet medical need. In this context, HER2 could be a relevant prognostic and predictive biomarker acting as a target for specific drugs. However, if the role of HER2 has been object of investigation for several years in gastric cancer, it is not well established in other GI malignancies. The aim of this narrative review was to portray the current landscape of the potential role of HER2 as a predictive biomarker for GI tumors beyond gastric cancer. In colon cancer, the benefit from anti-HER2 therapies is less clear than in gastric neoplasms for the lack of controlled studies. Pancreatic, biliary tract adenocarcinomas and hepatocarcinoma may derive a less clear clinical benefit by using anti-HER2 agents in HER2 positive tumors. Overall, the results are promising and seem to suggest that the integration of multiple modalities of therapies can optimize the cancer care. However, further prospective trials are needed to validate the use of personalized targeted therapies in this field.
Background: Patients receiving systemic anticancer therapy (SACT) can deteriorate clinically between scheduled appointments; yet, acute oncology services often rely on reactive helplines with limited longitudinal symptom visibility. Objective: The aim of this study was to evaluate the feasibility, safety, and workflow integration of OncsCare, a digital symptom triage platform mapping patient-reported symptoms to UK Oncology Nursing Society (UKONS) acuity tiers with episode-based clinician review. Methods: This 10-week service evaluation (July to September 2025) implemented OncsCare within a UK tertiary acute oncology service. Patients completed daily symptom check-ins mapped to UKONS-informed green/amber/red tiers. Alerts were grouped into episode-level triage events using prespecified rules (48-hour window, symptom-domain continuity) to represent the operational workload. Outcomes included engagement, alert distribution, escalation pathways, timeliness of clinical response, and safety signals via structured case-finding. Results: Thirty-two patients participated (none withdrew) in this study. Daily check-in completion rate was 91.7% (1444/1574 expected patient-days). From 362 amber/red alerts, 62 episodes were generated; 38.7% (24/62) were clinically actionable, resulting in telephone management (n=12, 50%), acute care assessment (n=9, 37.5%), emergency referral (n=2, 8.3%), or admission (n=1, 4.2%). Median time to first clinical response for in-hours red alerts was 47 minutes. Predefined safety case-finding identified no intervention-attributable safety signals. Patients reported increased home reassurance (n=17, 85%), and clinicians reported improved situational awareness without increased workload. Conclusions: UKONS-informed digital triage with episode-based review demonstrated feasibility, with no intervention-attributable safety signals identified in this small single-center evaluation. This operational model addresses alert fragmentation and supports prospective multicenter evaluation.
BACKGROUND Patients receiving systemic anticancer therapy (SACT) can deteriorate clinically between scheduled appointments; yet, acute oncology services often rely on reactive helplines with limited longitudinal symptom visibility. OBJECTIVE The aim of this study was to evaluate the feasibility, safety, and workflow integration of OncsCare, a digital symptom triage platform mapping patient-reported symptoms to UK Oncology Nursing Society (UKONS) acuity tiers with episode-based clinician review. METHODS This 10-week service evaluation (July to September 2025) implemented OncsCare within a UK tertiary acute oncology service. Patients completed daily symptom check-ins mapped to UKONS-informed green/amber/red tiers. Alerts were grouped into episode-level triage events using prespecified rules (48-hour window, symptom-domain continuity) to represent the operational workload. Outcomes included engagement, alert distribution, escalation pathways, timeliness of clinical response, and safety signals via structured case-finding. RESULTS Thirty-two patients participated (none withdrew) in this study. Daily check-in completion rate was 91.7% (1444/1574 expected patient-days). From 362 amber/red alerts, 62 episodes were generated; 38.7% (24/62) were clinically actionable, resulting in telephone management (n=12, 50%), acute care assessment (n=9, 37.5%), emergency referral (n=2, 8.3%), or admission (n=1, 4.2%). Median time to first clinical response for in-hours red alerts was 47 minutes. Predefined safety case-finding identified no intervention-attributable safety signals. Patients reported increased home reassurance (n=17, 85%), and clinicians reported improved situational awareness without increased workload. CONCLUSIONS UKONS-informed digital triage with episode-based review demonstrated feasibility, with no intervention-attributable safety signals identified in this small single-center evaluation. This operational model addresses alert fragmentation and supports prospective multicenter evaluation.